AstraZeneca granted PharmNovo AB a project application of novel delta agonists including 105 molecules, data and compound. The compounds and patent application were abandoned 2012 following invention of our own molecules.
VGR (Västra Götaland) fund PharmNovo with 0.4 million SEK.
VGR fund PharmNovo with 0.45 million SEK.
Two candidate selective and biased delta agonists chosen, PN6047 and PN6053.
Angel Investor funds PharmNovo with £200.000 + £100.000 on two occasions, 2014 and 2015.
PharmNovo UK Ltd started to work with novel small CGRP peptide antagonists for migraine treatment using novel formulation. 2017 funded for one year from Innovate UK in collaboration with Liverpool John Moores University.
Patent applications with PN6047, PN6053 and others.
Both patents withdrawn from Swedish Patent Office and resubmitted as PCT applications and further 2016 as European patent application and 2017 as world wide patent application.
Medical Research Council grant for three years approved with Eamonn Kelly, U. of Bristol,.
European patent demand defended.
New Capital investments in Q3 to finance patent costs and finalize pre-clinical studies. US patent granted for PN6047 in Q4 2018 and European patent in final approval process.
PHARMNOVO was founded in 2008 by Bengt von Mentzer after 27 years as a drug discovery group leader for Astra Zeneca. With a focus on chronic pain treatment PharmNovo started to develop novel delta opioid receptor agonists.
With chemist, Ingemar Starke, new chemistry was developed and we identified novel potent, selective and biased DOR agonists (a new concept in pharmacology at the time). In 2010, David Kendall, Professor of Pharmacology at Nottingham University joined the company part time and became full time CSO in 2015.
In 2016 a collaboration with Professor Eamon Kelly’s research group at the University of Bristol was started with the aim of studying delta opioid receptor biased agonism. This collaboration has been supported by grants from the UK Medical Research Council.